COSMOS Pharmaceutical Corporation (3349.T)

Positive revenue growth while 3391.T is negative. John Neff might see a notable competitive edge here.

Positive gross profit growth while 3391.T is negative. John Neff would see a clear operational edge over the competitor.

Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.

Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.

Positive net income growth while 3391.T is negative. John Neff might see a big relative performance advantage.

Positive EPS growth while 3391.T is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.

Positive diluted EPS growth while 3391.T is negative. John Neff might view this as a strong relative advantage in controlling dilution.

Share reduction more than 1.5x 3391.T's 0.01%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.

Slight or no buyback while 3391.T is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.

10Y revenue/share CAGR 1.25-1.5x 3391.T's 121.52%. Bruce Berkowitz would investigate brand strength or geographical expansion fueling growth.

5Y revenue/share CAGR above 1.5x 3391.T's 28.60%. David Dodd would look for consistent product or market expansions fueling outperformance.

3Y revenue/share CAGR above 1.5x 3391.T's 7.43%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.

Positive 10Y CAGR while 3391.T is negative. John Neff might see a substantial advantage in bottom-line trajectory.

Positive 5Y CAGR while 3391.T is negative. John Neff might view this as a strong mid-term relative advantage.

Positive short-term CAGR while 3391.T is negative. John Neff would see a clear advantage in near-term profit trajectory.

10Y equity/share CAGR above 1.5x 3391.T's 138.11%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.

5Y equity/share CAGR above 1.5x 3391.T's 36.92%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.

3Y equity/share CAGR above 1.5x 3391.T's 11.31%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.

5Y dividend/share CAGR above 1.5x 3391.T's 78.00%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.

3Y dividend/share CAGR above 1.5x 3391.T's 59.88%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.

We show growth while 3391.T is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.

Asset growth above 1.5x 3391.T's 1.17%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.

BV/share growth above 1.5x 3391.T's 0.38%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.

We have some new debt while 3391.T reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.

No Data available this quarter, please select a different quarter.